SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Indications -- HIV
An SI Board Since October 2004
Posts SubjectMarks Bans
155 12 0
Emcee:  tuck Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
130I remember Bristol-Myers-Squibb has a CCR2/CCR5 dual antagonist in preclinic stuidos-4/11/2010
129Merck now working on a dual ccr5/ccr2 antagonist: "Discovery of a Potent atuck-4/9/2010
128<b>Stem cells: home of HIV?</b> Posted by Jef Akst [Entry posted atidos13/17/2010
127<b>The New Battle Lines in HIV</b> <i>Updated info on GILD’s DewDiligence_on_SI-1/7/2010
126Contact: Michelle Gailiun michelle.gailiun@duke.edu 919-660-1306 Duke Universityidos112/16/2009
125An antiviral leash for HIV? Posted by Jef Akst [Entry posted at 29th October 200tnsaf-10/30/2009
124* SEPTEMBER 24, 2009, 6:58 A.M. ET Experimental HIV Vaccine Raises Hopes Assockenhott-9/24/2009
123Great work by the Protocol G team but will it deliver? not sure...idos-9/4/2009
122Antibodies found that prevent HIV from causing severe AIDS Scientists were ableElroy Jetson-9/4/2009
121HIV Market Data from GILD 2Q09 CC: siliconinvestor.comDewDiligence_on_SI-8/25/2009
120That's good news. This looks like the poster Jules abstracted his report froElroy Jetson-8/17/2009
119Shionogi/GSK think their agent will be better but too early to tell: natap.orgidos-8/17/2009
118Gilead certainly deserves the market dominance they own. Their HIV drug pipelineElroy Jetson-8/15/2009
117Isentress (raltegravir) is showing poor clinical durability, with patients quickElroy Jetson-8/15/2009
116You may be right but either way GILD will continue to dominate the front-line HIidos-8/15/2009
115Development of resistant isolates depends on mutations to acquire resistance. Tiidos-8/15/2009
114Elvitegravir is more potent than Isentress (raltegravir) on resistant viral isolElroy Jetson-8/14/2009
113I give the TMC278+Truvada combination a slight edge over GILD’s Quadro to becomeDewDiligence_on_SI18/14/2009
112I have never seen data to back your statement that elvitegravir has a far higheridos18/14/2009
111You're just a QD investor in a BID world.Elroy Jetson-8/14/2009
110The blockbuster integrase inhibitor should be Elvitegravir, because it has a farElroy Jetson-8/14/2009
109Only other integrase inhibitor being tested QD without a boosting agent that I kidos-8/14/2009
108It might work qD, but it's a long shot, IMO.DewDiligence_on_SI-8/14/2009
107You don't think it might work in a QD? MRK expects a QD filing in 2011.idos-8/14/2009
106Get off your soapbox—you're a bore and no one is listening.DewDiligence_on_SI-8/14/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News